Knight Therapeutics Inc (FRA:04K)
€ 3.42 -0.36 (-9.52%) Market Cap: 354.19 Mil Enterprise Value: 277.97 Mil PE Ratio: 0 PB Ratio: 0.67 GF Score: 88/100

Q4 2023 Knight Therapeutics Inc Earnings Call Transcript

Mar 21, 2024 / 12:30PM GMT
Release Date Price: €3.66 (+0.55%)
Operator

Good morning, ladies and gentlemen. My name is Sylvie and I will be your operator today. Welcome to Knight Therapeutics fourth-quarter and year-end 2023 results conference call. Before turning the call over to Samira Sakhia, President and CEO of Knight, listeners are reminded that portions of today's discussion may, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements.

The company considers these assumptions on which those forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the company and its subsidiaries, may ultimately prove to be incorrect.

The company disclaims any intentions or obligation to update or revise any forward-looking statements whether a results of new information or future events, except as required by law. We would also like to remind you questions during todayâs call will be taken from analysts only. Should there

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot